Navigation Links
Umbilical cord blood cell therapy in an animal model of Alzheimer's disease
Date:3/26/2008

New Rochelle, NY, March 26, 2008A novel strategy based on targeted immune suppression using human umbilical cord blood cells may improve the pathology and cognitive decline associated with Alzheimers disease, based on the results of a study in a mouse model of this currently untreatable neurodegenerative condition, as described in a groundbreaking report in Stem Cells and Development (www.liebertpub.com/scd), a peer-reviewed journal published by Mary Ann Liebert, Inc (www.liebertpub.com). The paper will be available free online (http://www.liebertonline.com/toc/scd/0/0).

Following a series of low-dose infusions of human umbilical cord blood cells into mice with Alzheimers-like disease, the amount of amyloid- and -amyloid plaqueshallmarks of Alzheimers pathology in the brainwas markedly reduced. Amyloid- induces an inflammatory response in the brain associated with the interaction of CD40 and CD40L, two pro-inflammatory molecules.

Human umbilical cord blood cell therapy was associated with suppression of CD40-CD40L activity, suggesting that this therapeutic approach modulates the activity of the immune system, offering the potential to target the pathogenic inflammatory response that may contribute to a variety of degenerative conditions, including Alzheimers disease.

Jun Tan, PhD, MD, and colleagues from USF (Tampa), Yale University (New Haven, CT), Cedars-Sinai Medical Center (Los Angeles, CA), Saneron CCEL Therapeutics (Tampa, FL), and Saitama Medical School (Japan), concluded that human umbilical cord blood cell-induced disruption of the CD40-CD40L interaction may alleviate the key pathologic changes in the brain associated with Alzheimers disease in a report entitled, Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice.

Previously, challenging observations have reported phenomena suggesting the non-hematologic therapeutic potential of blood stem cells. What is novel about this paper is its application to Alzheimers disease, and a significant advance in characterizing the ameliorative mechanism of action says Graham C. Parker, PhD, Editor-in-Chief of Stem Cells and Development, and a research professor in The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
2. Diabetes makes it hard for blood vessels to relax
3. Weill Cornell team discovers how brains own tPA helps regulate blood flow to neurons
4. High blood pressure in older adults traced to genes effects in blood vessels
5. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
6. MIT works toward engineered blood vessels
7. Blood pressure drug telmisartan shows powerful activity against stroke
8. Protein controls blood vessel formation, offers new drug target
9. Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
10. Study of malaria parasite in patient blood finds distinct physiological states
11. Blood clotting protein linked to rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... Research and Markets has announced the addition of the ... offering. ... The global bioinformatics market is ... Billion in 2016, growing at a CAGR of 21.1% during the ... driven by the growing demand for nucleic acid and protein sequencing, ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... (PRWEB) , ... December 06, ... ... of the Almac Group, the world’s largest privately-held contract pharmaceutical development and ... inVentiv Health, a leading biopharma outsourcing company combining a leading CRO and ...
(Date:12/6/2016)... ... December 06, 2016 , ... Symbios Technologies, ... that the company has engaged in a collaborative research partnership with Colorado State ... CSU Office of the Vice President for Research. This agreement is designed to ...
(Date:12/6/2016)... , Dec. 6, 2016 Zimmer Biomet Holdings, ... announced the pricing terms of its previously-announced cash ... aggregate purchase price (excluding accrued and unpaid interest ... and excluding fees and expenses related to the ... securities identified in the table below (collectively, the ...
(Date:12/6/2016)... ... December 06, 2016 , ... RoviSys, a ... headquartered in Aurora, Ohio, announced the opening of their new office building today. ... constructed facility is home to 200 employees focused on providing sales, engineering, and ...
Breaking Biology Technology: